- A conversation with Julie Holland, MD
MDMA-assisted therapy was on the brink of FDA approval in 2024 but faced an unexpected setback when the FDA rejected the application. This decision has sent ripples of confusion through the psychedelic community, leaving clinicians and researchers uncertain about the next steps. Is another Phase 3 clinical trial necessary? How should the field respond, and what can be learned from this pivotal moment?
Tonight's conversation
Julie Holland, psychiatrist, researcher, and best-selling author, has been at the forefront of psychedelic research and advocacy for over two decades. In this webinar, she meets clinical psychologist Filip Bromberg for an insightful discussion on navigating the uncertainty following the FDA’s decision. They will examine the clinical implications, ethical dilemmas, strategies for harm reduction, and the relational elements vital for effective MDMA therapy. What lessons can Sweden and the global psychedelic community learn as they move forward from this challenging juncture? Join us for an engaging and critical dialogue exploring the challenges and opportunities ahead.
About Julie Holland
Dr. Julie Holland is a psychiatrist specializing in psychopharmacology, with extensive experience in psychedelic research. She served as a psychiatrist at Bellevue Hospital's psychiatric emergency room in New York City for nearly a decade. Holland is the editor of "Ecstasy: The Complete Guide" and author of several influential books, including "Good Chemistry" and "Moody Bitches." A recognized voice in psychedelic science, she is a medical advisor to MAPS (Multidisciplinary Association for Psychedelic Studies) and a leading advocate for evidence-based, compassionate, and ethical psychedelic therapies. Dr. Holland will also be a keynote speaker at the upcoming Borealis Psychedelic Science Summit in Stockholm, September 27–28, 2025.
About Lavin
This webinar is brought to you by Borealis Psychedelic Science Summit, in collaboration with the Swedish Psychedelic Education Company Lavin.
Lavin is a new platform for education and training, integrating scientific and clinical expertise with harm-reduction principles to support the safe and ethical use of psychedelics. Lavin offers high-quality courses for healthcare professionals with a uniquely Swedish perspective. Its mission is to build a professional community and a solid foundation for the future implementation of psychedelic-assisted treatments in Sweden.
If you have any questions, please contact [email protected].
